Business Description
Genscript Biotech Corp
ISIN : KYG3825B1059
Share Class Description:
GNNSF: Class HCompare
Compare
Traded in other countries / regions
01548.Hong KongGNNSF.USAG51.Germany IPO Date
2017-07-24Description
GenScript Biotech is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. The company estimates that more than two-thirds of GenScript's valuation is from its ownership stake in Legend.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.62 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -1.67 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.86 | |||||
| Beneish M-Score | -1.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.9 | |||||
| 3-Year EBITDA Growth Rate | 3 | |||||
| 3-Year EPS without NRI Growth Rate | 20.1 | |||||
| 3-Year FCF Growth Rate | -13.1 | |||||
| 3-Year Book Growth Rate | 6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 49.09 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 7.08 | |||||
| 9-Day RSI | 5.34 | |||||
| 14-Day RSI | 7.51 | |||||
| 6-1 Month Momentum % | -29.7 | |||||
| 12-1 Month Momentum % | -21.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.76 | |||||
| Quick Ratio | 4.65 | |||||
| Cash Ratio | 3.9 | |||||
| Days Inventory | 46.55 | |||||
| Days Sales Outstanding | 63.05 | |||||
| Days Payable | 38.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -33.57 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.78 | |||||
| Operating Margin % | -47.55 | |||||
| Net Margin % | -11.39 | |||||
| FCF Margin % | -52.96 | |||||
| ROE % | -7.65 | |||||
| ROA % | -3.08 | |||||
| ROIC % | -32.83 | |||||
| ROC (Joel Greenblatt) % | -46.16 | |||||
| ROCE % | -12.4 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.02 | |||||
| PB Ratio | 2.44 | |||||
| Price-to-Tangible-Book | 2.49 | |||||
| EV-to-EBIT | -5.35 | |||||
| EV-to-Forward-EBIT | -13.59 | |||||
| EV-to-EBITDA | -6.94 | |||||
| EV-to-Forward-EBITDA | -16.86 | |||||
| EV-to-Revenue | 2.06 | |||||
| EV-to-Forward-Revenue | 5.45 | |||||
| EV-to-FCF | -3.89 | |||||
| Price-to-Net-Current-Asset-Value | 9.8 | |||||
| Earnings Yield (Greenblatt) % | -18.69 | |||||
| FCF Yield % | -13.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:GNNSF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genscript Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 839.529 | ||
| EPS (TTM) ($) | -0.045 | ||
| Beta | 0.58 | ||
| Volatility % | 51.38 | ||
| 14-Day RSI | 7.51 | ||
| 14-Day ATR ($) | 0.011874 | ||
| 20-Day SMA ($) | 1.4905 | ||
| 12-1 Month Momentum % | -21.88 | ||
| 52-Week Range ($) | 1.47 - 3.2 | ||
| Shares Outstanding (Mil) | 2,124.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genscript Biotech Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genscript Biotech Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genscript Biotech Corp Frequently Asked Questions
What is Genscript Biotech Corp(GNNSF)'s stock price today?
The current price of GNNSF is $1.47. The 52 week high of GNNSF is $3.20 and 52 week low is $1.47.
When is next earnings date of Genscript Biotech Corp(GNNSF)?
The next earnings date of Genscript Biotech Corp(GNNSF) is 2024-08-21 Est..
Does Genscript Biotech Corp(GNNSF) pay dividends? If so, how much?
Genscript Biotech Corp(GNNSF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers